Site is Being Upgraded

Lighting your way to lower cholesterol, and triglycerides levels: Intense blue light exposure decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 16/November/2018, 11.48 pm

Lengthening the lifespan of mighty humans with a tiny Probiotic Lactobacillus reuteri GMNL-263: Probiotic Lactobacillus reuteri GMNL-263 may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others longevity-promoting genes, 16/November/2018, 11.34 pm
November 16, 2018
Valproic acid-based therapy for blood sugar disease: Valproic acid  increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 16/October/2018, 11.57 pm
November 16, 2018
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests, first the first time, a blue light-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD).

Intense blue light exposure, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Intense blue light exposure-based therapy, either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  intense blue light exposure decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Intense blue light functions as a cholesterol-lowering agent. Exposure to intense blue light lowers cholesterol and triglyceride levels and attenuates NAFLD through down-regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  Intense blue light exposure decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Lighting your way to lower cholesterol, and triglycerides levels: Intense blue light exposure decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 16/November/2018, 11.48 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.